Cencora (NYSE:COR) Issues FY 2026 Earnings Guidance

by · The Markets Daily

Cencora (NYSE:COR – Get Free Report) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 17.450-17.75 for the period, compared to the consensus EPS estimate of 17.440. The company issued revenue guidance of $337.4 billion-$343.8 billion, compared to the consensus revenue estimate of $342.1 billion.

Analyst Upgrades and Downgrades

COR has been the topic of several analyst reports. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Evercore ISI set a $400.00 price target on Cencora and gave the stock an “outperform” rating in a research note on Thursday. UBS Group upped their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday. Morgan Stanley set a $330.00 price objective on Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Finally, Wells Fargo & Company lifted their price objective on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $351.50.

View Our Latest Stock Analysis on COR

Cencora Stock Performance

Shares of COR stock traded up $0.32 during mid-day trading on Friday, reaching $360.56. 1,300,741 shares of the company’s stock traded hands, compared to its average volume of 1,540,871. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The firm has a market capitalization of $69.90 billion, a PE ratio of 37.09, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. Cencora has a 12 month low of $223.92 and a 12 month high of $364.36. The firm has a 50 day moving average price of $312.89 and a two-hundred day moving average price of $298.79.

Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter in the prior year, the business posted $3.34 earnings per share. The business’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts forecast that Cencora will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a $0.60 dividend. The ex-dividend date is Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 22.63%.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 41,544 shares of company stock worth $12,230,941 over the last 90 days. Insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

Hedge funds have recently made changes to their positions in the company. MUFG Securities EMEA plc bought a new position in Cencora during the second quarter valued at approximately $152,000. ICONIQ Capital LLC purchased a new stake in shares of Cencora during the 2nd quarter worth approximately $207,000. Ausdal Financial Partners Inc. bought a new position in shares of Cencora during the 2nd quarter valued at approximately $221,000. State of Wyoming boosted its position in shares of Cencora by 44.2% during the 2nd quarter. State of Wyoming now owns 1,070 shares of the company’s stock valued at $321,000 after acquiring an additional 328 shares during the last quarter. Finally, Modern Wealth Management LLC grew its holdings in shares of Cencora by 7.6% in the second quarter. Modern Wealth Management LLC now owns 1,118 shares of the company’s stock valued at $335,000 after purchasing an additional 79 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

About Cencora

(Get Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Featured Stories